Pharmaceutical manufacturer Zydus Cadila said that it received final approval from the United States Food and Drug Administration (USFDA) for the sales of a generic equivalent of Nexium Delayed-Release capsules manufactured by Teva Pharmaceutical Industries.
Esomeprazole, which belongs to a class of medicines called proton pump inhibitors, works by reducing the the amount of acid secreted by the stomach. It is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers and to treat patients with stomach infection.
The capsules, in doses of 25 mg and 40 mg, will be manufactured at Zydus’ manufacturing facility at Ahmedabad.
With the latest approval, Zydus has so far received far received 266 approvals and filed over 350 applications for sales of its generic drugs.
Headquartered in Ahmedabad, Zydus Cadila has manufacturing sites and research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim and in the United States and Brazil.